NOVEN ANNOUNCES RESULTS OF 2008 ANNUAL MEETING OF STOCKHOLDERS |
BackMiami, FL, June 5, 2008 -- Noven Pharmaceuticals, Inc. (NASDAQ: NOVN) today announced the results of its 2008 Annual Meeting of Stockholders. At the meeting held earlier today, stockholders elected the following persons to Noven’s Board of Directors:
| • | Sidney Braginsky – President and Chief Executive Officer, Atropos Technology Inc.; | |
| • | Peter Brandt – Noven’s President and Chief Executive Officer; | |
| • | John G. Clarkson, M.D. – Executive Director of the American Board of Ophthalmology and Dean Emeritus and Professor of Ophthalmology, University of Miami Miller School of Medicine; | |
| • | Donald A. Denkhaus – Executive Chairman, TM Systems, LLC; | |
| • | Pedro P. Granadillo – Senior Vice President – Global Manufacturing and Human Resources (Retired), Eli Lilly & Company; | |
| • | Phillip M. Satow – Co-founder and former Chief Executive Officer of JDS Pharmaceuticals, LLC; | |
| • | Robert G. Savage – Worldwide Chairman, Pharmaceutical Group (Retired), Johnson & Johnson; and | |
| • | Wayne P. Yetter – Chief Executive Officer, Verispan LLC, and non-executive Chairman of the Board of Noven. |
Stockholders
also ratified the appointment of Deloitte & Touche LLP as Noven’s
independent registered public accounting firm for 2008. At the meeting,
Peter Brandt, Noven’s President and Chief Executive Officer, made
a presentation regarding Noven’s business and prospects. A webcast
replay of the meeting will be available at www.noven.com for at least
two weeks.
About Noven
Noven Pharmaceuticals, Inc. is a specialty pharmaceutical
company engaged in the research, development, manufacture, marketing
and sale of prescription pharmaceutical products. Noven’s business
and operations are focused in three principal areas – transdermal
drug delivery, the Novogyne joint venture, and its Noven Therapeutics
specialty pharmaceutical unit.
Contact:
|
Copyright © 2008 Noven Pharmaceuticals, Inc. All rights reserved.